Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Tedisamil (Solvay).

¹Imperial College School of Medicine, Academic Cardiology Unit, National Heart and Lung Institute Division, London, UK. n.flores@ic.ac.uk

Current Opinion in Investigational Drugs (London, England : 2000)

|August 31, 2001

Summary

Tedisamil, a potassium channel blocker, shows promise for treating atrial fibrillation. It effectively terminates and prevents atrial fibrillation in canine models without negatively impacting myocardial function.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Divergence between respirometry and physicochemical methods in the fractionation of the chemical oxygen demand in municipal wastewater.

Water environment research : a research publication of the Water Environment Federation·2011

Same author

Changes in extracellular pH and myocardial ischaemia alter the cardiac effects of diadenosine tetraphosphate and pentaphosphate.

British journal of pharmacology·2001

Same author

Contribution of nitric oxide and prostanoids to the cardiac electrophysiological and coronary vasomotor effects of diadenosine polyphosphates.

The Journal of pharmacology and experimental therapeutics·2001

Same author

Coronary vasomotor and cardiac electrophysiologic effects of diadenosine polyphosphates and nonhydrolyzable analogs in the guinea pig.

Journal of cardiovascular pharmacology·2001

Same author

Investigation of mechanisms that mediate reactive hyperaemia in guinea-pig hearts: role of K(ATP) channels, adenosine, nitric oxide and prostaglandins.

British journal of pharmacology·2001

Same author

Products of the platelet release reaction influence cardiac electrophysiology independently of platelet-platelet interactions.

Platelets·2000

Area of Science:

Pharmacology
Cardiology
Electrophysiology

Background:

Tedisamil is a novel potassium channel blocker investigated for cardiac conditions.
It is classified as a class III anti-arrhythmic agent.
Solvay is developing tedisamil, currently in Phase II trials for atrial fibrillation.

Purpose of the Study:

To evaluate the efficacy and safety of tedisamil in treating atrial fibrillation.
To investigate the electrophysiological effects of tedisamil on cardiac potassium channels.
To assess tedisamil's impact on myocardial function and hemodynamics.

Main Methods:

Preclinical studies in rat, rabbit, canine, and simian hearts.
Canine models of exercise-induced angina and induced atrial fibrillation.
Electrophysiological assessments of potassium channel activity and action potential duration.
Hemodynamic monitoring including diastolic arterial pressure.

Main Results:

Tedisamil demonstrated a marked prolongation of action potential by modulating potassium channels.
The drug rapidly terminated sustained atrial fibrillation and prevented its reinitiation in canine models.
Tedisamil exhibited bradycardic effects without negative inotropic effects, maintaining myocardial function in canine angina models.
Diastolic arterial pressure remained uninfluenced by tedisamil.

Conclusions:

Tedisamil's class III antiarrhythmic effect is primarily due to potent blockade of the rapid component of the delayed rectifier potassium current.
Tedisamil shows significant potential for the treatment of atrial fibrillation.
The drug's favorable hemodynamic profile and lack of negative inotropic effects warrant further clinical investigation.

Related Experiment Videos